Hot Features
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome prolifer... Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.13 | 4.20032310178 | 3.095 | 3.26 | 2.885 | 3024 | 3.12645129 | DE |
| 4 | -0.03 | -0.921658986175 | 3.255 | 3.69 | 2.885 | 2973 | 3.25437831 | DE |
| 12 | -1.595 | -33.0912863071 | 4.82 | 5.05 | 2.885 | 1855 | 3.78139459 | DE |
| 26 | -0.75 | -18.8679245283 | 3.975 | 6.16 | 2.885 | 2218 | 4.67338724 | DE |
| 52 | 0.565 | 21.2406015038 | 2.66 | 6.16 | 2.595 | 3119 | 4.12473648 | DE |
| 156 | -0.04 | -1.22511485452 | 3.265 | 6.16 | 1.452 | 1956 | 3.67880305 | DE |
| 260 | -0.04 | -1.22511485452 | 3.265 | 6.16 | 1.452 | 1956 | 3.67880305 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.